Clinical trial readout dates for Jazz Pharmaceuticals plc, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Zanidatamab Gastric Neoplasms; Gastroesophageal Adenocarcinoma · NCT05152147 | July 2026 Primary data collected |
| Phase 2 Zanidatamab Breast Cancer; Gastric Cancer · NCT06695845 | December 2026 Recruiting |
| Phase 3 Xywav Narcolepsy; Idiopathic Hypersomnia · NCT07625280 | December 2027 Recruiting |
| Phase 2 Zanidatamab HER2-positive Breast Cancer; Breast Cancer · NCT07102381 | December 2027 Recruiting |
| Phase 1/2 Lurbinectedin Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma · NCT05734066 | January 2028 Recruiting |
| Phase 3 Zanidatamab Metastatic HER2-positive Breast Cancer · NCT06435429 | April 2028 Recruiting |
| Phase 3 Dordaviprone (ONC201) H3 K27M; Glioma · NCT05580562 | June 2028 Recruiting |
| Phase 2/3 JZP926 capsule Juvenile Myoclonic Epilepsy · NCT07723963 | August 2028 Recruiting |
| Phase 2 JZP3507 Meningioma · NCT07533942 | October 2028 Recruiting |
Jazz Pharmaceuticals plc reported $2.86B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $483M; at that rate the cash would last about 6 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-02 |
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-10-26 |